Postmodern Studio / Shutterstock.com
13 June 2022Big Pharma
Teva settles patent dispute with Aurobindo
Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Generics
6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Europe
11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
Editor's picks
Editor's picks
Generics
6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Europe
11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
Generics
6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Americas
10 August 2022 Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Europe
11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.